Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (94) Bactroban Nasal 2% (mupirocin calcium ointment), SmithKline Beecham,
...intranasally administered topical agent for the eradication of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA). This treatment has been approved for adult subjects and health care workers as part of a comprehensive infection control program to reduce the risk of MRSA infection during institutional outbreaks of infections with this pathogen. A problem first confined to tertiary ...
View Page

2.  Study Posting (4409) Trial #162793, Wounds, St. Petersburg, FL
...clinical and bacteriological efficacy of retapamulin in the treatment of subjects with impetigo due to MRSA. Patient Inclusion Description: 2 months of age, diagnosis of secondarily-infected traumatic lesion or impetigo ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (177), Skin Infections/Disorders
...was 0.06 and 0.12 micrograms/mL, respectively. Delafloxacin's MIC90 values against all MRSA, including the quinolone-resistant MRSA strains, was also 0.06 micrograms/mL. Delafloxacin was safe and well tolerated. Overall treatment ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (465), Bacterial Infections
...was 0.06 and 0.12 micrograms/mL, respectively. Delafloxacin's MIC90 values against all MRSA, including the quinolone-resistant MRSA strains, was also 0.06 micrograms/mL. Delafloxacin was safe and well tolerated. Overall treatment ...
View Page

5.  Study Posting (1843) Trial #141939, Skin Infections/Disorders, Baton Rouge, LA
...years old or older with diagnosis of complicated skin and skin structure infection such as MRSA which involves deeper soft tissue such as major abscess, infected burn, traumatic wound infection, deep ...
View Page

6.  Study Posting (4179) Trial #120662, Diabetic Foot Ulcers, Evanston, IL
...administration for up to 28 consecutive days. Subjects receiving ertapenem may also receive vancomycin for MRSA, coagulase-negative staphylococci (CNS), or enterococci coverage at the investigator’s discretion. Goal: This is ...
View Page

7.  CenterWatch Clinical Research Profile (5290) Trial #2169, PACT, Phoenix, AZ
...Hematology Anemia, deep vein thrombosis, hyponatremia Immunology/Infectious Disease Bacteremia, coccidiodomycosis, intra-abdominal infection, MAC, MRSA, severe sepsis, VAP/MRSA, VREF infection Metabolic/Endocrine Diabetic neuropathy, diabetes type 1, diabetes type 2 Musculoskeletal Osteoporosis, premenopausal ...
View Page

8.  CenterWatch: New Medical Therapies in Disease Category (167), Pneumonia
...II, enrolled 1,503 subjects, 464 of whom were infected with methicillin-resistant Staphylococcus aureus (MRSA). The subjects received either telavancin 10 mg/kg intravenously once daily or vancomycin 1 g ...
...and superiority in clinical cure rate of telavancin versus vancomycin in the pooled subjects with MRSA infections from both trials. Both endpoints were achieved. In the combined clinically evaluable population, the ...
View Page

9.  CenterWatch: New Medical Therapies in Disease Category (799), Staphylococcal Skin Infections
...93.1% in Staphylococcus aureus infections in the microbiologically evaluable population and 93.3% for MRSA infections. Treatment was well tolerated, with an adverse events profile similar between the two treatment ...
...83.5% and 84.7% for iclaprim and linezolid respectively and for methicillin-resistant strains (MRSA) 77.0% and 80.0%, respectively. The incidence of drug-related adverse events was higher ...
View Page

10.  CenterWatch Clinical Research Profile (3262) Trial #1525, Century Clinical Research, Inc, Houston, TX
...ER driven pneumonia, and COPD Cardiovascular Hypertension and hyperlipidemia, Heart Attack Prevention Infectious Disease Complicated (MRSA) and uncomplicated wound Endocrinology Diabetes type II, Naïve Diabetes Gyne/ Urology Urinary tract infection, erectile ...
View Page

11.  Newly Approved Drug Therapies (1055) Vibativ (telavancin), Theravance,
...14 days. The trials enrolled 1,794 adult subjects with cSSSI with suspected or confirmed MRSA as the primary cause of infection. Of the 1,794 enrolled subjects, 1,410 (78 ...
View Page

12.  CenterWatch Clinical Research Profile (3707) Trial #1638, Nevada Center for Dermatology, Reno, NV
...areas include basal cell carcinoma, actinic damage, psoriasis, eczema, herpes, acne, infectious diseases (e.g., MRSA), onychomycosis, rosacea and dermatitis in both adults and children. In addition to standard research methods ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (372), Vaccines
...gram-positive and gram-negative organisms isolated from patients in the study, including 100% of MRSA isolates inhibited at 0.5 mg/L or less. Safety data revealed a positive adverse ...
...muscle and/or fascia infections caused by streptococci and staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). Based on these results, the company plans to initiate a phase III trial program. VaxGen ...
View Page

14.  CenterWatch: New Medical Therapies in Disease Category (179), HIV Infections
...gram-positive and gram-negative organisms isolated from patients in the study, including 100% of MRSA isolates inhibited at 0.5 mg/L or less. Safety data revealed a positive adverse ...
View Page